Table 2.
Summary of functional assay results for HLX01, CN-rituximab and EU-rituximab.
| Sample | CD20-binding mean |
FcRn-binding mean |
FcγRIa-binding mean |
FcγRIIa-binding mean |
FcγRIIb/c-binding mean |
FcγRIIIa(V) -binding mean |
FcγRIIIa(F) -binding mean |
FcγRIIIb-binding mean |
C1q-binding mean |
CDC mean |
ADCC mean |
Apoptosis mean |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (range) | (range) | (range) | (range) | (range) | (range) | (range) | (range) | (range) | (range) | (range) | (range) | |
| HLX01 | 107% | 113% | 103% | 102% | 90% | 95% | 98% | 102% | 102% | 107% | 95% | 99% |
| (83–123%) | (98%–143%) | (93%–124%) | (97%–109%) | (81%–99%) | (84%–101%) | (89%–118%) | (93%–116%) | (90%–115%) | (83%–119%) | (77%–110%) | (73%–114%) | |
| CN-rituximab | 91% | 131% | 99% | 105% | 99% | 85% | 80% | 85% | 102% | 107% | 77% | 98% |
| (77–110%) | (110%–174%) | (80%–110%) | (98%–111%) | (83%–114%) | (74%–102%) | (67%–100%) | (72%–100%) | (91%–122%) | (93–127%) | (63–97%) | (61–121%) | |
| EU-rituximab | 102% | 121% | 118% | 109% | 100% | 84% | 76% | 90% | 106% | 115% | 83% | 97% |
| (81%–117%) | (96%–155%) | (111%–124%) | (104%–113%) | (69%–123%) | (76%–93%) | (64%–89%) | (83%–99%) | (101%–114%) | (90–133%) | (62–107%) | (68–112%) |